ArticleFrontiers in medicine2025
The effect of atorvastatin combined with azithromycin on lung function and right heart function in COPD patients with concomitant pulmonary hypertension.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) often coexists with pulmonary hypertension (PH), leading to exacerbated morbidity and mortality. Conventional treatments focus on bronchodilation, anti-inflammatory agents, and vasodilators, emphasizing the need for novel interventions. Atorvastatin and azithromycin have pleiotropic properties that may benefit COPD with concomitant PH. However, the combined impact of these medications on lung and right heart function in this patient population remains underexplored. Methods: A retrospective cohort study involving 229 stable COPD patients with concomitant PH assessed the effects of atorvastatin combined with azithromycin. Patients were divided into atorvastatin monotherapy and atorvastatin plus azithromycin combination therapy groups and underwent a 6-month treatment period. Blood testing, pulmonary function testing, and echocardiographic assessment of right heart function were conducted before and after treatment. Results: The combination therapy group exhibited significant improvements in blood gas indicators (mean PaO Conclusion: This retrospective study suggests potential associations between combination therapy with atorvastatin and azithromycin and improvements in functional outcomes in COPD patients with concomitant PH. These findings warrant prospective validation in randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.